Published in Int J Radiat Oncol Biol Phys on March 01, 2010
Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA (2012) 5.90
Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys (2011) 1.76
A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy. BMC Urol (2013) 1.03
Quantifying Unnecessary Normal Tissue Complication Risks due to Suboptimal Planning: A Secondary Study of RTOG 0126. Int J Radiat Oncol Biol Phys (2015) 0.96
Impact of dose to the bladder trigone on long-term urinary function after high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys (2014) 0.95
Whole pelvic intensity-modulated radiotherapy for high-risk prostate cancer: a preliminary report. Radiat Oncol J (2013) 0.94
Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer. EBioMedicine (2016) 0.90
Transitioning from conventional radiotherapy to intensity-modulated radiotherapy for localized prostate cancer: changing focus from rectal bleeding to detailed quality of life analysis. J Radiat Res (2014) 0.87
Image-guided radiation therapy for muscle-invasive bladder cancer. Nat Rev Urol (2011) 0.87
The effect of anterior proton beams in the setting of a prostate-rectum spacer. Med Dosim (2013) 0.83
Sensitivity analysis for lexicographic ordering in radiation therapy treatment planning. Med Phys (2012) 0.83
Displacements of fiducial markers in patients with prostate cancer treated with image guided radiotherapy: A single-institution descriptive study. Rep Pract Oncol Radiother (2014) 0.82
Interactive dose shaping part 2: proof of concept study for six prostate patients. Phys Med Biol (2016) 0.82
Dose-response of acute urinary toxicity of long-course preoperative chemoradiotherapy for rectal cancer. Acta Oncol (2014) 0.81
Prospective phase II study of image-guided local boost using a real-time tumor-tracking radiotherapy (RTRT) system for locally advanced bladder cancer. Jpn J Clin Oncol (2013) 0.81
Dosimetric evaluation of synthetic CT relative to bulk density assignment-based magnetic resonance-only approaches for prostate radiotherapy. Radiat Oncol (2015) 0.80
Developing a class solution for Prostate Stereotactic Ablative Body Radiotherapy (SABR) using Volumetric Modulated Arc Therapy (VMAT). Radiother Oncol (2013) 0.79
Evaluating the Role of Urinalysis for Suspected Cystitis in Women Undergoing Pelvic Radiotherapy. Int J Gynecol Cancer (2016) 0.78
Urethral strictures after radiation therapy for prostate cancer. Investig Clin Urol (2016) 0.78
Treatment-related complications of radiation therapy after radical prostatectomy: comparative effectiveness of intensity-modulated versus conformal radiation therapy. Cancer Med (2014) 0.77
Urinary bladder dose-response relationships for patient-reported genitourinary morbidity domains following prostate cancer radiotherapy. Radiother Oncol (2016) 0.77
Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer. Radiat Oncol (2015) 0.77
mARC vs. IMRT radiotherapy of the prostate with flat and flattening-filter-free beam energies. Radiat Oncol (2014) 0.77
Focal therapy, differential therapy, and radiation treatment for prostate cancer. Adv Urol (2012) 0.77
Promising results with image guided intensity modulated radiotherapy for muscle invasive bladder cancer. Radiat Oncol (2015) 0.76
Long-term Outcomes and Late Effects of Definitive Chemoradiotherapy in Patients with Cervical Cancer in Nova Scotia. Cureus (2015) 0.76
Personalized treatment planning with a model of radiation therapy outcomes for use in multiobjective optimization of IMRT plans for prostate cancer. Radiat Oncol (2016) 0.75
Equivalence of Gyn GEC-ESTRO guidelines for image guided cervical brachytherapy with EUD-based dose prescription. Radiat Oncol (2013) 0.75
Helical tomotherapy of spinal chordomas: French Multicentric, retrospective study of a cohort of 30 cases. Radiat Oncol (2017) 0.75
Delivery parameter variations and early clinical outcomes of volumetric modulated arc therapy for 31 prostate cancer patients: an intercomparison of three treatment planning systems. ScientificWorldJournal (2013) 0.75
A treatment planning study comparing tomotherapy, volumetric modulated arc therapy, Sliding Window and proton therapy for low-risk prostate carcinoma. Radiat Oncol (2016) 0.75
An integrated strategy of biological and physical constraints in biological optimization for cervical carcinoma. Radiat Oncol (2017) 0.75
Role of Dose Intensification for Salvage Radiation Therapy after Radical Prostatectomy. Front Oncol (2016) 0.75
A modeling study of functional magnetic resonance imaging to individualize target definition of seminal vesicles for external beam radiotherapy. Acta Oncol (2017) 0.75
Dose planning objectives in anal canal cancer IMRT: the TROG ANROTAT experience. J Med Radiat Sci (2015) 0.75
Dosimetric and radiobiological impact of intensity modulated proton therapy and RapidArc planning for high-risk prostate cancer with seminal vesicles. J Med Radiat Sci (2016) 0.75
Comparison of dosimetric parameters and acute toxicity after whole-pelvic vs prostate-only volumetric-modulated arc therapy with daily image guidance for prostate cancer. Br J Radiol (2016) 0.75
Acute and late urinary toxicity following radiation in men with an intact prostate gland or after a radical prostatectomy: A secondary analysis of RTOG 94-08 and 96-01. Urol Oncol (2016) 0.75
An investigation of the dose distribution effect related with collimator angle in volumetric arc therapy of prostate cancer. J Med Phys (2016) 0.75
Computational methods using genome-wide association studies to predict radiotherapy complications and to identify correlative molecular processes. Sci Rep (2017) 0.75
Comparison of four 3D conformal treatment techniques to optimise radiotherapy treatment for anal cancer. J Med Radiat Sci (2014) 0.75
Integrative review on the non-invasive management of lower urinary tract symptoms in men following treatments for pelvic malignancies. Int J Clin Pract (2015) 0.75
Estimation of kidneys and urinary bladder doses based on the region of interest in (18)fluorine-fluorodeoxyglucose positron emission tomography/computed tomography examination: a preliminary study. Quant Imaging Med Surg (2017) 0.75
Simultaneous integrated boost intensity-modulated radiotherapy versus 3-dimensional conformal radiotherapy in preoperative concurrent chemoradiotherapy for locally advanced rectal cancer. Radiat Oncol J (2017) 0.75
Simple diagrammatic method to delineate male urethra in prostate cancer radiotherapy: an MRI based approach. Br J Radiol (2016) 0.75
Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol (2004) 4.69
Time course and incidence of late complications in patients treated with radiation therapy for FIGO stage IB carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys (1995) 4.26
Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys (2008) 3.61
Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol (2002) 3.49
Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys (2008) 2.33
Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys (2005) 2.31
Dose and volume parameters for MRI-based treatment planning in intracavitary brachytherapy for cervical cancer. Int J Radiat Oncol Biol Phys (2005) 1.86
Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology (2002) 1.71
Urological complications of cyclophosphamide. J Urol (1989) 1.69
Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys (1997) 1.65
The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy. Int J Radiat Oncol Biol Phys (1995) 1.58
Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys (2007) 1.54
Figo IIIB squamous cell carcinoma of the cervix: an analysis of prognostic factors emphasizing the balance between external beam and intracavitary radiation therapy. Int J Radiat Oncol Biol Phys (1999) 1.54
Urodynamic and ultrasound characteristics of incontinence after radical hysterectomy. Neurourol Urodyn (2007) 1.46
Comparison between CT-based volumetric calculations and ICRU reference-point estimates of radiation doses delivered to bladder and rectum during intracavitary radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys (2005) 1.33
Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.32
Correlation of smoking history and other patient characteristics with major complications of pelvic radiation therapy for cervical cancer. J Clin Oncol (2002) 1.30
Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer. J Urol (2002) 1.30
Magnetic resonance-guided interstitial therapy for vaginal recurrence of endometrial cancer. Int J Radiat Oncol Biol Phys (2006) 1.28
Organ motion, set-up variation and treatment margins in radical radiotherapy of urinary bladder cancer. Radiother Oncol (2003) 1.20
Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. J Clin Oncol (1998) 1.16
Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience. Cancer (2008) 1.10
An analysis of the radiation related morbidity observed in a randomized trial of neutron therapy for bladder cancer. Int J Radiat Oncol Biol Phys (1986) 1.09
Radiotherapy for muscle-invasive carcinoma of the bladder: results of a randomized trial comparing conventional whole bladder with dose-escalated partial bladder radiotherapy. Int J Radiat Oncol Biol Phys (2004) 1.09
Late gastrointestinal morbidity after three-dimensional conformal radiation therapy for prostate cancer fades with time in contrast to genitourinary morbidity. Int J Radiat Oncol Biol Phys (2007) 1.08
Comparison of radiography- and computed tomography-based treatment planning in cervix cancer in brachytherapy with specific attention to some quality assurance aspects. Radiother Oncol (2001) 1.08
The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy. Radiother Oncol (1986) 1.05
Three-dimensional treatment planning of intracavitary gynecologic implants: analysis of ten cases and implications for dose specification. Int J Radiat Oncol Biol Phys (1994) 1.04
Inter fraction variations in rectum and bladder volumes and dose distributions during high dose rate brachytherapy treatment of the uterine cervix investigated by repetitive CT-examinations. Radiother Oncol (2001) 1.04
Tolerance and early outcome results of postprostatectomy three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys (1997) 1.00
CT-assisted assessment of bladder and rectum dose in gynecological implants. Int J Radiat Oncol Biol Phys (1987) 0.99
Concomitant boost radiotherapy for muscle invasive bladder cancer. Radiother Oncol (2003) 0.98
Urinary tract dysfunction after radical hysterectomy for cervical cancer. Gynecol Oncol (2002) 0.95
Deformable structure registration of bladder through surface mapping. Med Phys (2006) 0.95
Bladder movement during radiation therapy for bladder cancer: implications for treatment planning. Int J Radiat Oncol Biol Phys (1997) 0.92
Maximum and mean bladder dose defined from ultrasonography. Comparison with the ICRU reference in gynaecological brachytherapy. Radiother Oncol (1994) 0.92
Hypofractionated radiotherapy for invasive bladder cancer. Radiother Oncol (1997) 0.88
Accelerated superfractionated radiotherapy with concomitant boost for invasive bladder cancer. Int J Radiat Oncol Biol Phys (2003) 0.86
A randomised trial of accelerated radiotherapy for localised invasive bladder cancer. Radiother Oncol (2004) 0.84
Primary radical radiotherapy for T3 transitional cell cancer of the bladder: an analysis of survival and control. Int J Radiat Oncol Biol Phys (1986) 0.80
Evaluating the effect of reducing the high-dose volume on the toxicity of radiotherapy in the treatment of bladder cancer. Clin Oncol (R Coll Radiol) (2006) 0.80
Conservation of bladder function in patients with invasive bladder cancer treated by definitive irradiation and selective cystectomy. Int J Radiat Oncol Biol Phys (1981) 0.79
Prostate cancer: post-irradiation incontinence. J Urol (1990) 0.79
Invasive bladder cancer treated by radical external radiotherapy. Br J Urol (1985) 0.78
A feasibility study of accelerated fractionation in radiotherapy of carcinoma of the urinary bladder. Int J Radiat Oncol Biol Phys (1997) 0.78
Prostatic carcinoma: complications of megavoltage radiation therapy. Br J Urol (1986) 0.78
Results of a randomised study to evaluate influence of dose on morbidity in radiotherapy for bladder cancer. Clin Radiol (1985) 0.78
A randomised comparison of photons and 15 MeV neutrons for the treatment of carcinoma of the bladder. Br J Radiol (1985) 0.78
Split-course radiotherapy of carcinoma of the urinary bladder stages C and D1. A Radiation Therapy Oncology Group Study. Am J Clin Oncol (1985) 0.78
Bladder carcinoma. Experience with radical and preoperative radiotherapy in 421 patients. Cancer (1985) 0.78
Radiotherapy in multiple fractions per day for prostatic carcinoma: late complications. Int J Radiat Oncol Biol Phys (1986) 0.77
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys (2006) 11.17
Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med (2011) 7.46
Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol (2008) 4.69
Bladder cancer. Lancet (2009) 4.43
Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys (2010) 4.33
Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol (2003) 4.33
Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys (2009) 3.91
Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol (2011) 3.17
Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys (2010) 2.94
How long have I had my cancer, doctor? Estimating tumor age via Collins' law. Oncology (Williston Park) (2011) 2.84
Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys (2012) 2.80
Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol (2008) 2.68
Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys (2010) 2.66
Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. Eur Urol (2012) 2.61
Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys (2003) 2.58
Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison. Int J Radiat Oncol Biol Phys (2007) 2.55
Bladder cancer. J Natl Compr Canc Netw (2013) 2.46
Prone positioning causes the heart to be displaced anteriorly within the thorax: implications for breast cancer treatment. Int J Radiat Oncol Biol Phys (2008) 2.39
Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys (2010) 2.32
Variability of target and normal structure delineation for breast cancer radiotherapy: an RTOG Multi-Institutional and Multiobserver Study. Int J Radiat Oncol Biol Phys (2009) 2.27
Acute skin toxicity following stereotactic body radiation therapy for stage I non-small-cell lung cancer: who's at risk? Int J Radiat Oncol Biol Phys (2008) 2.20
Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol (2008) 2.20
ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol (2012) 2.19
Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer. JAMA (2010) 2.16
Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer (2013) 2.10
Local recurrence after surgery for early stage lung cancer: an 11-year experience with 975 patients. Cancer (2009) 2.08
Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J Clin Oncol (2002) 2.00
COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol (2007) 1.95
The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Semin Radiat Oncol (2008) 1.93
PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys (2005) 1.83
Radiation dose-volume effects in the esophagus. Int J Radiat Oncol Biol Phys (2010) 1.78
Local recurrence following initial resection of NSCLC: salvage is possible with radiation therapy. Cancer J (2006) 1.76
Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys (2004) 1.76
Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). J Am Coll Surg (2009) 1.76
Long-term quality of life outcome after proton beam monotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys (2011) 1.75
Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial. J Natl Cancer Inst (2009) 1.75
Measurement of lung tumor motion using respiration-correlated CT. Int J Radiat Oncol Biol Phys (2004) 1.74
Assessment of the residual error in soft tissue setup in patients undergoing partial breast irradiation: results of a prospective study using cone-beam computed tomography. Int J Radiat Oncol Biol Phys (2007) 1.73
Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys (2010) 1.72
Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol (2003) 1.72
The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome. Int J Radiat Oncol Biol Phys (2010) 1.65
Bronchial stenosis: an underreported complication of high-dose external beam radiotherapy for lung cancer? Int J Radiat Oncol Biol Phys (2005) 1.64
Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups. Int J Radiat Oncol Biol Phys (2006) 1.62
Multi-institutional review of repeat irradiation of chest wall and breast for recurrent breast cancer. Int J Radiat Oncol Biol Phys (2007) 1.61
The role of radiation therapy in preventing regional recurrences of invasive squamous cell carcinoma of the vulva. Int J Radiat Oncol Biol Phys (2003) 1.60
Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys (2006) 1.60
Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. Gynecol Oncol (2004) 1.58
One to three versus four or more positive nodes and postmastectomy radiotherapy: time to end the debate. J Clin Oncol (2008) 1.54
Point: Hyperthermia with radiation for chest wall recurrences. J Natl Compr Canc Netw (2007) 1.49
Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence. Gynecol Oncol (2004) 1.49
Long-term changes in pulmonary function tests after definitive radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys (2003) 1.49
Predicting radiotherapy-induced cardiac perfusion defects. Med Phys (2005) 1.47
Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer (2005) 1.47
Comparing radical prostatectomy and brachytherapy for localized prostate cancer. Oncology (Williston Park) (2004) 1.46
The use and QA of biologically related models for treatment planning: short report of the TG-166 of the therapy physics committee of the AAPM. Med Phys (2012) 1.46
Patterns of regional recurrence after definitive radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys (2009) 1.45
Improving normal tissue complication probability models: the need to adopt a "data-pooling" culture. Int J Radiat Oncol Biol Phys (2010) 1.44
Radiation-induced lung injury. Assessment, management, and prevention. Oncology (Williston Park) (2008) 1.44
Normal tissue effects: reporting and analysis. Semin Radiat Oncol (2003) 1.44
Benchmarks achieved in the delivery of radiation therapy for muscle-invasive bladder cancer. Urol Oncol (2007) 1.44
The CT motion quantitation of lung lesions and its impact on PET-measured SUVs. J Nucl Med (2004) 1.44
Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol (2002) 1.41
Long-term durability of PSA failure-free survival after radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys (2002) 1.40
Self-consistent tumor control probability and normal tissue complication probability models based on generalized EUD. Med Phys (2007) 1.40
Elective nodal irradiation for locally advanced non-small-cell lung cancer: it's called cancer for a reason. Int J Radiat Oncol Biol Phys (2009) 1.38
Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy. Int J Radiat Oncol Biol Phys (2003) 1.36
Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol (2009) 1.35
Comparison between CT-based volumetric calculations and ICRU reference-point estimates of radiation doses delivered to bladder and rectum during intracavitary radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys (2005) 1.33
Challenges in defining radiation pneumonitis in patients with lung cancer. Int J Radiat Oncol Biol Phys (2005) 1.33
Bladder cancer. J Natl Compr Canc Netw (2009) 1.32
Radiation dose-volume effects of optic nerves and chiasm. Int J Radiat Oncol Biol Phys (2010) 1.31
Radiation dose-volume effects and the penile bulb. Int J Radiat Oncol Biol Phys (2010) 1.30
Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis. Int J Radiat Oncol Biol Phys (2013) 1.29
Intensity-modulated radiation therapy after hysterectomy: comparison with conventional treatment and sensitivity of the normal-tissue-sparing effect to margin size. Int J Radiat Oncol Biol Phys (2005) 1.29
Myocardial perfusion changes in patients irradiated for left-sided breast cancer and correlation with coronary artery distribution. Int J Radiat Oncol Biol Phys (2003) 1.28
Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31. Cancer (2007) 1.28
Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10. Clin Cancer Res (2004) 1.28
RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys (2003) 1.26
Dosimetric and clinical predictors for radiation-induced esophageal injury. Int J Radiat Oncol Biol Phys (2005) 1.26
Cervical cancer. J Natl Compr Canc Netw (2013) 1.24
Acute and late toxicity after dose escalation to 82 GyE using conformal proton radiation for localized prostate cancer: initial report of American College of Radiology Phase II study 03-12. Int J Radiat Oncol Biol Phys (2010) 1.24
A methodology for using SPECT to reduce intensity-modulated radiation therapy (IMRT) dose to functioning lung. Int J Radiat Oncol Biol Phys (2006) 1.24
Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02. Clin Cancer Res (2007) 1.22
Primary malignant melanoma of the vagina. Obstet Gynecol (2010) 1.22
A method for evaluating quality assurance needs in radiation therapy. Int J Radiat Oncol Biol Phys (2008) 1.22
Thermochemoradiotherapy improves oxygenation in locally advanced breast cancer. Clin Cancer Res (2004) 1.21
Salvage radiotherapy after radical prostatectomy for prostate adenocarcinoma: analysis of efficacy and prognostic factors. Urology (2002) 1.19
The atlas of complication incidence: a proposal for a new standard for reporting the results of radiotherapy protocols. Semin Radiat Oncol (2006) 1.18
Comparison of heart and coronary artery doses associated with intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for distal esophageal cancer. Int J Radiat Oncol Biol Phys (2012) 1.17
Definitive radiation therapy for squamous cell carcinoma of the vagina. Int J Radiat Oncol Biol Phys (2005) 1.16